Skip to content

Guaranteeing the Continuity of the Care Pathway for the Elderly Patient: Evaluation of a Territorial Approach of Clinical Pharmacy

Eval CONPARMED Haute-Bretagne : Guaranteeing the Continuity of the Care Pathway for the Elderly Patient: Evaluation of a Territorial Approach of Clinical Pharmacy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04018781
Acronym
CONPARMED
Enrollment
443
Registered
2019-07-15
Start date
2019-06-13
Completion date
2020-02-13
Last updated
2021-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medication Reconciliation at Discharge

Keywords

Medication reconciliation, clinical pharmacy

Brief summary

In the context of the ageing of the French population, drug iatrogeny in the elderly is a major public health issue, responsible for approximately 7,500 deaths per year and 3.4% of hospitalizations among patients aged 65 and over. The interest of the Medication Reconciliation (MR) in reducing medication errors and unintentional discrepancies in prescriptions at transition points in patients' medication care pathways no longer seems to be in doubt both in France and abroad. On the other hand, the literature on the clinical impact of these drug errors (i. e. occurrence of an adverse drug event (ADE) or readmission rates) is currently limited in France and presents variable results abroad.

Detailed description

The medication reconciliation implementation mobilizes human resources (pharmacists, pharmacy technician, nurses...) and constitutes an investment for healthcare institutions. However, the resulting improvement in patients' health status (and the potential reduction in ADEs) could reduce their care consumption and thus reduce costs from a healthcare system perspective. We therefore propose to assess the cost-effectiveness of this care strategy. Finally, we will study the impact of the MR deployment on existing professional organizations, both in hospital and between community healthcare professionals and hospital as well as its conditions of implementation.

Interventions

OTHERmedication reconciliation

During hospitalization, the hospital pharmacist will carry out a pharmaceutical analysis for all patients included in the study, each time the prescription is changed and within a maximum of 24 hours (working days). If necessary, in consultation with the doctor in charge of the patient, the pharmacist may also propose a pharmaceutical interview to the patient at any time during his hospitalisation (e.g. proposal for the de-prescription of benzodiazepines, Proton Pump Inhibitors, etc., according to the recommendations in force).

Sponsors

Ecole des Hautes Etudes en Santé Publique
CollaboratorOTHER
Rennes University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

: * Patient \> 65 years old * Patient hospitalized inside one of the thirteen wards in the 6 hospitals participating in the study * Informed consent given Non inclusion and

Exclusion criteria

: * Patients in palliative care * Persons deprived of their liberty

Design outcomes

Primary

MeasureTime frameDescription
Adverse drug event-related hospital revisits30 days after dischargeRate of adverse drug event-related hospital revisits within 30 days after discharge

Secondary

MeasureTime frameDescription
All-causes readmissions and/or Emergency Department visits30 days after dischargeComposite rate of readmissions and/or Emergency Department visits within 30 days after discharge
Incremental Cost-Effectiveness Ratio (ICER) at Day 3030 days after dischargeMedico-economic analysis : Incremental Cost-Effectiveness Ratio (ICER) : cost per hospitalization for Drug Adverse Event avoided and cost per all-causes hospitalization, according to a collective perspective at Day 0.
Incremental Cost-Effectiveness Ratio (ICER) at Day 9090 days after dischargeMedico-economic analysis : Incremental Cost-Effectiveness Ratio (ICER) : cost per hospitalization for Drug Adverse Event avoided and cost per all-causes hospitalization, according to a collective perspective at Day 90.
General Practitioner consultation30 days after dischargeRate of General Practitioner consultation within 30 days after discharge
Severity of Unintended Medication DiscrepanciesAt admissionSeverity of Unintended Medication Discrepancies intercepted during medication reconciliation at admission
Number of Unintended Medication DiscrepanciesAt admissionNumber of Unintended Medication Discrepancies intercepted during medication reconciliation at admission
Impact of the implementation of the intervention on professional organizationsBefore and after the implementation of the intervention in the participating wardsQualitative analysis based on : * First, an inventory of organizations prior to the implementation of the intervention in participating health facilities * Then, an assessment of the impacts of the implementation of the intervention on different aspects of professional organizations: collaborative exchanges, multi-professional information sharing, division of labour, exchanges with city practitioners, learning effects, evolution of professional practices.
Patient reported experience measures7 days after dischargePatient reported experience measures are realized by a short phone call interview, 7 days after the patients' homecoming

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026